entertainment

ith nearly 5 million confirmed cases worldwide and more than 300,000 deaths from COVID-19 , much is still unknown about SARS-CoV-2 , the virus that causes the disease. Two critical questions are whether the vaccines will prevent infection with the new coronavirus and whether people who have recovered from COVID-19 are protected against re-exposure to the virus, something that a preliminary Spanish study questioned these days . Now, a couple of new studies led by researchers at the Beth Israel Deaconess Medical Center ( BIDMC ) in Boston suggest that the answer to these questions is yes, at least in animal models. The results of these studies on protection against reinfection , and on protection of a potential DNA vaccine , were published today in the journal  Science. poker poker poker poker poker poker poker poker poker poker poker poker poker poker poker poker poker poker poker poker poker poker poker poker poker poker poker poker poker poker poker poker poker poker

n the last hours, the encouraging news about possible vaccines against COVID-19, yes, in phases of study still early. According to new research published in  The Lancet ,  the first anti-COVID-19 vaccine to reach the phase 1 clinical trial was found to be safe, well tolerated, and capable of eliciting an immune response against SARS-CoV-2 in humans. . The open trial by Chinese scientists on 108 healthy adults shows promising results after 28 days; the final results will be evaluated in six months. However, further testing is needed to determine whether the immune response it elicits effectively protects against SARS-CoV-2 infection. “These results represent an important milestone. The trial shows that a single dose of the new type of vectorized adenovirus 5 vaccine COVID-19 (Ad5-nCoV) produces virus and T-cell-specific antibodies in 14 days, making it a potential candidate for further research. " , says Professor Wei Chen of the Beijing Biotechnology Institute,in China, who is res